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affected countries of other regions imply that the various impacts of the disease will 
be smaller in South Asia than in the worst affected countries in other regions. While 
justified with respect to the impact of the disease on economic output, on poverty, or 
on orphanhood, this conclusion does not follow with respect to the health sector, 
where the relatively minor public role in health care delivery and the entrepreneurial 
and heterogeneous private health and pharmaceutical sectors combine to magnify 
the potential impact of the epidemic. 
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HIV/AIDS in South Asian countries and alternative scenarios regarding future 
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burden that their governments will shoulder if they decide to provide or finance all of 
the needed care. Since AIDS treatment cannot be presumed to slow HIV 
transmission and may speed it, the usual argument for paying for such treatment 
with public funds is on equity grounds—that it will prevent poverty and orphanhood. 
Indeed this paper estimates that public financing of AIDS treatment might avert 
poverty for about three percent of the Indian population, for example.  However, 
data on the quality of private health care in India suggests that another effect of 
publicly produced AIDS treatment would be to crowd out lower-quality private AIDS 
treatment, thereby preventing some of the negative spillovers of poor quality private 
treatment. The paper closes by arguing on efficiency grounds that the government 
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AIDS Treatment in South Asia: Equity and Efficiency Arguments for Shouldering 




In South Asia HIV and AIDS are less prevalent than in sub-Saharan Africa or in severely 
affected countries of the Caribbean, South East Asia or the Pacific Islands. The slower 
spread of AIDS, combined with the fact that most South Asian countries have higher per 
capita incomes than the most severely affected countries of other regions suggest that the 
various impacts of the disease will be smaller in South Asia than in other regions. While this 
conclusion is generally justified with respect to the impact of the disease on economic 
output, on poverty or on orphanhood, it does not necessarily follow with respect to the 
health sector, where particular features of supply and demand can magnify the impact of 
any given rate of HIV infection. 
Our analysis is broadly divided into two main parts. The first part of the chapter takes 
stock of the scale of the challenge to health sectors in South Asia. This part sets out with an 
overview of the numbers of AIDS cases and the availability of treatment in South Asia 
(Section 2), including a review of the available evidence regarding the provision of 
antiretroviral therapy through public and private health services. The following Section 3 
looks forward, providing new estimates of the costs of AIDS treatment through the year 
2020 for 6 South Asian countries,
2 on the assumption that countries will attempt to provide 
universal access to AIDS treatment. 
The second part of the chapter considers the implications of specific features of the 
supply and demand for health care in South Asia for the impact of the projected increased 
demand for AIDS treatment on South Asian health sectors, focusing on the roles of the 
private vs. the public health care providers. This emphasis reflects the fact that the public 
health systems of the South Asian region provide a much smaller proportion their citizens’ 
                                             
1 This paper was made possible by financial support from the Bill & Melinda Gates Foundation. The 
author is grateful to Agnes Couffinal, Paolo Belli, Charlie Griffin and Phil Musgrove for detailed 
comments and to Martina Tonizzo for expert research assistance.  The author also thanks Mariam 
Claeson and Markus Haacker, without whose patient unceasing support this paper would not exist.   
Thanks also to John Stover who generously commented on early versions of the projection model 
presented in Annex 3 and used for the projections of treatment and fiscal loads in section IV of the 
paper and to Martina Tonizzo for research assistance. The model constructed by Stover and Bollinger 
using Spectrum has similar objectives to the one developed here. (http://www.futuresinstitute.org/ 
and 
http://www.unaids.org/en/MediaCentre/PressMaterials/FeatureStory/20070925_Resource_needs_met
hodology.asp).  An earlier version of this paper appears as a chapter in Claeson and Haacker (2009). 
2 Owing to data constraints, the analysis presented in this chapter focuses on Bangladesh, Bhutan, 
India, Nepal, Pakistan and Sri Lanka, and excludes Afghanistan and the Maldives.    2   
 
health care than do the systems of countries outside the region which are severely affected 
by AIDS (Section 4). With the notable exception of Sri Lanka, three-quarters or more of 
health expenditures in the region are financed privately, and little or none of the private 
payments are mediated by third-party payers like insurance agencies. The fact that much of 
South Asia is poorly provided with public facilities or public sector health finances suggests 
that many of these people who would in other countries frequent the public facilities, will 
instead seek care from a nearby private practitioner, either modern or traditional. 
In a context where public health services and third-party payers like insurance agencies 
play a relatively minor role, the high costs of antiretroviral therapy (ART) have implications 
for access to such treatment and expose households to the risk of poverty. Section 5 
discusses the impact of health expenditures on poverty in general, and arrives at 
conjectures regarding the impacts of HIV/AIDS-related health expenditures on poverty.  
Since AIDS treatment cannot be presumed to slow HIV transmission and may speed it, 
the usual argument for paying for such treatment with public funds is on equity grounds - 
that it will prevent poverty and orphanhood.  However, Section 6 of this chapter argues that 
publicly produced AIDS treatment might crowd out lower quality private AIDS treatment, 
thereby preventing some negative spillovers of poor quality treatment.   The section reviews 
the evidence that suggests that this effect of public treatment might be sufficient to justify 
government support on efficiency grounds. 
Finally, a concluding section summarizes the findings of the chapter, and suggests their 
policy implications for South Asian governments. 
Overview of AIDS cases and treatment in South Asia 
Knowledge of the burden of AIDS in South Asia became dramatically more precise with the 
release in 2006 of the country’s first population-based survey which collected and analyzed 
blood samples in order to accurately measure the proportion of India’s population that is 
infected with HIV. Since India is the region’s largest country, the adjustment of its 
estimated prevalence rate from almost one percent early in 2006 down to approximately 0.3 
percent after release of the survey has erased more than three million putative cases of HIV 
infection from the region.  
The implications of this correction for the epidemiology and the economic impact of 
AIDS in India are addressed elsewhere (Claeson and Haacker, 2009, various chapters). Here 
it is sufficient to note that a smaller prevalence rate means that the epidemic has caused a 
smaller increase in the demand for health care than might previously have been 
conjectured. Figure 1 shows the distribution of the current burden of disease, showing that 
HIV/AIDS accounts for 1½ percent of all deaths in South Asia and about 2 percent of all 
deaths in India. Haacker (ibid, chapter 3) points out that these numbers of deaths are 
comparable to the numbers from diabetes, tuberculosis and measles.    3   
 
What will these pie charts look like in the future? Recent evidence suggests that, in 
accordance with the pattern typically observed during an epidemiologic transition, measles 
is declining as a cause of death in the region, while diabetes and tuberculosis are both 
increasing. While diabetes is a life-style disease associated with the increasing prevalence of 
obesity, tuberculosis is an opportunistic illness which takes advantage of weakened immune 
systems, and thus can be spread by AIDS. Thus, if HIV continues to spread at the rate it 
has spread in the past, it is likely to become substantially more important than measles and 
may outpace diabetes. Whether HIV or TB will grow faster will depend on the vigor of 
programs to prevent and treat them. 


























Source: Haacker (present volume). 
Table 1 presents estimates by WHO, UNAIDS and UNICEF (2008) of the number of 
people receiving AIDS treatment and the number needing it in each South Asian country. 
While the number of people receiving treatment is based on real, even if somewhat 
incomplete, data from regional health ministries, the number of people estimated to need 
treatment is extrapolated from epidemiologic projection models and is thus dependent on 
the available HIV prevalence data.    4   
 
 
Table 1.  Estimated Numbers of People Requiring and Receiving ART, end-2007 
 
   People receiving ART  People needing ART 












Bangladesh  <200  <200  2 400  1 500   4 000
Bhutan  <100 <100 <100 <100  <100
India   158 000   138 000  178 000 …  630 000  1 600 000
Nepal   1 400   1 300  1 600  20 000  13 000   30 000
Pakistan    600    500   600  20 000  13 000   34 000
Sri Lanka  <200  <100 <200   780   540   1 100
Source: All figures except those for India’s need are from World Health Organization, UNAIDS, 
UNICEF, "Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector," 
Progress Report, June 2008. Need for ART in India is missing in the 2008 report so this table uses 
figures from the 2007 issue of the same report. (ART = antiretroviral therapy for AIDS) 
 
In India, the recently announced adjustments in the estimated number of HIV infected 
give credence to the lower estimate of 630,000 needing treatment and suggest that the 
upper estimate of 1.6 million is obsolete. Since the ratio of those receiving treatment to 
those needing it is defined as the coverage rate, the choice of 630,000 as the denominator 
means that India has achieved a fifteen percent coverage rate rather than only a six percent 
coverage, welcome news to those striving for maximal coverage. 
Figure 2 presents data on the scale up of central government financed antiretroviral 
therapy (ART) to a total of about 56,500 patients in January, 2007. The most remarkable 
feature of the scale-up depicted in Figure 2 is its constantly increasing upward slope. Like 
Thailand, Botswana and a few other countries, India has been able to accelerate its 
treatment program during the launch phase. While one can ask whether the patient 
numbers represent surviving patients or replacements recruited when a patient dies or is 
lost-to-follow-up, the achievement of continued acceleration over a three year period is 
remarkable and sets a high standard for coming years.    5   
 
Figure 2. HIV Treatment in Centers Supported by the Indian National AIDS Control Organization, 
India, April 2004 through January 2007. 
 
Source: NACO as cited by Steinbrook, 2007.  WHO (2008) cites newer NACO figures which count 
118,052 people receiving ART in December, 2007 at 137 sites. 
Estimates for the number of patients receiving ART in India from non-governmental 
sources are extremely conjectural. Steinbrook (2007) estimates between 10,000 and 
20,000. WHO’s April 2007 progress report gives an estimate of 25,000 receiving ART in the 
unorganized or “unstructured” private health sector (see WHO, UNAIDS, and UNICEF 
(2007)). This brings the estimated total under treatment in 2006 to about 95,000.  By 
December, 2007, the updated WHO report estimates a total of 158,000 under treatment, 
including about 5,000 treated by NGOs and 35,000 in the for-profit private sector.  Thus for 
two years running the Indian government has estimated that it is treating three out of four 
Indian ART patients, with one out of four being treated in the formal and informal private 
sector. Since the private sector provides over 80 percent of all health care in India, these 
estimates suggest that Indians depend much more on the public sector for AIDS treatment 
than they do for other health care services.  
It is also possible, however, that NACO and WHO have greatly underestimated the 
amount of private sector provision. For example, using data from two surveys of Indian 
physicians, one by mail and another conducted by the representatives of a major 
pharmaceutical firm, a study performed in 2002 found substantial ART prescribing among 
non-government physicians (Hira, 2002). The representativeness of neither of these two 
samples can be assured. The former suffered from a response rate of only 30 percent, while 
the latter was a convenience sample selected by the pharmaceutical company, which is 
likely to be biased towards high-volume prescribers. Within the sample collected by the 
pharmaceutical companies, about a third of the respondents were employed by government 
hospitals, while 46 % were in private clinics and 22 % in Trust Hospitals. Given that many 
of the government employees in the sample also practice part time from private clinics, this 
distribution plausibly captures some features of the population of Indian physicians.    6   
 
Respondents were asked whether they prescribed antiretroviral medications. Their self-
reported answers were coded as “Never”, “Occasionally” or “Frequently”. Figure 3 presents 
the results. Note that the more independent of the government was the affiliation of the 
physician, the more likely he was to prescribe ART, with the highest frequency being in 
practitioners in private clinics.  This was in 2002, before India began to expand availability 
of ART with the establishment of AIDS Treatment Centers. The pattern partly reflects the 
fact that the pharmaceutical company was approaching and surveying its usual clients, who 
are probably high-volume prescribers. However, even taking this possible source of bias into 
account, the pattern shows that many private sector physicians were fully engaged in ART 
treatment. 
Figure 3. Percent of physicians who report prescribing ART “frequently”  




Assuming these surveys to be representative, a perhaps heroic assumption, the authors 
of the study estimated that about 90,000 Indians were receiving ART in 2002 at a time 
when the government was formally delivering treatment to only a few thousand patients. 
Thus an upper bound to the number of patients receiving ART in the private sector in 2005 
is on the order of 100,000 – 200,000. Assuming that most of the patients previously treated 
in the private sector in 2005 remain under treatment in the private sector, then the 118,000 
patients receiving government financed ART in December 2007 are only one-third to one-
half of all the Indians currently under treatment.  Thus, it is safe to say that somewhere 
between 25 and 67 percent of AIDS care in India is currently being delivered by the private 
sector.    7   
 
Future growth of South Asian treatment costs 
For patients who benefit from antiretroviral therapy, AIDS is a chronic disease. Given 
current technology, patients will need to take their AIDS medication every day for the rest 
of their lives. Thus, the fiscal and organizational burden of treating AIDS patients 
accumulates over time as patients who begin treatment each year are added to the stock of 
patients still alive from previous years. 
Figures 4 and 5 present the projected burden of treatment costs for two of the South 
Asian countries, India and Nepal. Both figures are generated by the same model which is 
described in Annex 3. Given assumptions regarding the success of antiretroviral therapy and 
the rate of new cases of HIV infection, the calculations presented in these figures are based 
on the assumption that all South Asian countries adopt much more rapid scale up of anti-
retroviral therapy consistent with the ambition to achieve “universal coverage” as quickly as 
possible (Shrestha, Bhatta, and Bhatta, 2006). The four panels in the two figures present 
the projected number of patients (in the northwest panel), the costs of the program in each 
year (in the northeast corner), the percentage of the cost for those remaining from previous 
years, here called the “entitlement”, (in the southwest corner) and the treatment cost as a 
percent of health and total public expenditure (southeast).
3 
The first thing to note in comparing the figures for India and Nepal is the difference in 
scale, measured on the vertical axis in each of the four panels. While India’s number of 
patients on treatment rises from less than 100,000 to 2.5 million in the year 2020, Nepal’s 
number is 30 times smaller, rising to about 100,000 at the end of the period. Similarly the 
ratio between projected annual AIDS expenditures in the year 2020 also differ by a factor of 
30, with India projected to spend about 2 billion dollars that year and Nepal “only” 60 
million dollars.  
Among other assumptions detailed in Annex 3, the model assumes that 4 percent of 
those who survive one year on AIDS treatment will experience “treatment failure” each year 
and then be given much more expensive “second line” therapy.  We assume that on top of 
a constant $278 per year in clinic time, first-line drugs cost $227 a year, while second-line 
therapy costs $2,681.  As a result of these assumptions, the projections for both India and 
Nepal (and for the other countries shown in Annexes 1 and 2) the portion of total costs 
consumed by second-line therapies is much larger than the portion of patients who receive 
them. (Compare the line for second-line patients in the northwest quadrant with the line for 
second-line patients in the northeast quadrant.)  By 2020 more than 20 percent of 
                                             
3 Figures 4 and 5 share the assumption that the “incidence rate” of new cases declines at a modest 5 
percent each year from its historical level. This assumption is also embodied in the two right-hand 
tables in Annex 4. 
    8   
 
treatment costs will be for second-line therapy, a fact that raises the urgency of efforts to 
bring down the cost of these more sophisticated and newer AIDS drugs.
4  
Government will also want to know what share of their various budgets will be 
consumed by the accumulating costs of AIDS treatment. One way to address this issue is to 
project forward each country’s total health expenditure under the assumption that it 
remains the same percentage of GDP as in 2004 (the last year for which we have data). The 
southeast panel of the two figures shows the projections that AIDS treatment in India will 
rise to absorb about 6 percent of the central health budget, while in Nepal it would rise to 
consume about a fifth of the health care budget. Of course in both countries, the health 
budget might be expanded in order to absorb AIDS treatment expenditure, meaning that 
the major cost of AIDS treatment would be foregone funding in sectors from which the 
funds are reallocated.  
These projections for India and Nepal both assume rapid scale-up of ART, indeed more 
rapid than was promised by the Indian National AIDS Control Organization in its various 
announcements. At the other extreme, suppose that countries are only able to maintain the 
rate of scale up that they have already demonstrated since 2003/4. As we saw for India in 
Figure 2, this “historical” rate of expansion has been steady and accelerating, but moderate. 
The result will be much lower costs in the year 2020. Comparing the top and bottom rows 
of Annex 4, we can see that rapid scale-up will cost about 6 times as much per year by the 
year 2020, compared to historical scale-up. Of course, under slower scale up the countries 
will lose millions of people to AIDS deaths who might otherwise have had extended lives. 
                                             
4 The greatest uncertainty in these projections is with regards to the annual cost of second-line 
therapy.  While the costs of clinic time and of first-line therapy are unlikely to change much, second 
line therapy could either decline or increase in average cost.  Second line prices might decline due to 
negotiated price reductions and/or exercise of TRIPS provisions which allow a country to issue a 
“compulsory license” for domestic manufacture of a pharmaceutical product under certain conditions.  
But there will be upward pressure on second line costs from the advent of newer medications, the 
increasing complexity of care for patients who fail first-line treatment, the usual increase in costs with 
increasing scale and the globalization of the Indian pharmaceutical industry.  Since the outcome of 
these conflicting trends is not clear, the projections presented here assume that unit costs remain 
constant for both first- and second-line medications.    9   
 

























Total number on ART Number on 2nd Line

































2005 2010 2015 2020



















2005 2010 2015 2020


















2005 2010 2015 2020
ART % Pub HE ART % Total HE
ART % Cntrl Gov Exp
Adjusting at 95.0 % of unmet need each year
adrate1 = .13, adrate2 = .04, bdrate = .01, Erate = .11, ndrate = .3, incdwn = .95
Total for country IND
AIDS Treatment: Numbers, costs & entitlement
 
Source: Author’s projections. 


























Total number on ART Number on 2nd Line
































2005 2010 2015 2020



















2005 2010 2015 2020


















2005 2010 2015 2020
ART % Pub HE ART % Total HE
ART % Cntrl Gov Exp
Adjusting at 95.0 % of unmet need each year
adrate1 = .13, adrate2 = .04, bdrate = .01, Erate = .11, ndrate = .3, incdwn = .95
Total for country NPL
AIDS Treatment: Numbers, costs & entitlement
 
Source: Author’s projections.    10   
 
Annex 1 presents similar projections for the South Asian countries of Bangladesh, 
Bhutan, Sri Lanka and Pakistan. Annex 2 presents a single graph for the aggregates across 
all the countries of South Asia (comparable to the tables in Annex 4) and a second single 
graph for all of sub-Saharan Africa. Sub-Saharan Africa as a unit is projected to be treating 
30 million people by the year 2020 at an annual cost of 25 billion dollars. In the absence of 
assistance, AIDS treatment will be amount to about 80 per cent of what would have been 
the health budget of the average African country. Since Africa benefits from greater inflows 
of grant support for AIDS treatment than does South Asia, African governments may not be 
asked to cover a large share of these extraordinary costs.
5 
Health care financing in South Asian countries 
Although per capita incomes are higher in South Asia than in many African countries, the 
two continents are on a par with respect to total health expenditure per capita. Figure 6 
presents a box and whisker plot showing on the left side the distribution of total health 
expenditure per capita in the six South Asian countries and on the right the distribution of 
the same variable for sub-Saharan Africa. Although there are several outliers above the 
African graph, capturing the wealthiest countries on that continent, the center of the 
distribution is similar in both cases, with the median for both distributions being under $20 
per person. 
                                             
5 The magnitude of AIDS treatment funding relative to health system capacity may crowd out funding 
of other health system activities in recipient countries (Over, 2004).  And the magnitude of such 
funding relative to total foreign assistance by any given donor may crowd out other types of foreign 
assistance at the source, particularly for the largest bilateral donor (Over, 2008).    11   
 
Figure 6. Total health expenditure per capita is similar in South Asia and sub-Saharan Africa,  



































































Graphs by WB's Region Code, 2007
 
Source: Author’s construction from World Bank (2007). 
The importance of the private health care sector in a country can be analyzed from 
either the production or the expenditure perspective. Table 2 presents data on the 
production side of the Indian health sector from the period 1986 through 1995. The public 
share of both public and private health care production clearly declined in that decade with 
the private share reaching 80 percent of outpatient care and almost 60 percent of inpatient 
care (Sengupta and Nundy (2005)). Data from the 2004 National Sample Survey shows no 
change in private sector dominance of out-patient care and increased private sector 
dominance of inpatient care.
6 In view of the growth of the private sector Indian economy 
since 1995 and the greatly increased inequality of the income distribution, it would not be 
surprising to find that the private component accounted for an even larger share of the 
health care sector in 2008 than it did in 2004.  Since successful AIDS treatment is delivered 
on an out-patient basis, these data support the view that many Indian patients are likely to 
seek and receive ART from the private sector.   
                                             
6 Thanks to an anonymous reviewer for supplying the 2004 figures for this table.  The data is 
advertised on the web site of the statistical office at http://mospi.nic.in/mospi_nsso_data.htm.    12   
 
Table 2.  Shares of Private and Public Health Care Production in India, 
    
 1986-87  1995-96  2004 
  Rural Urban Rural Urban Rural Urban 
Not treated  18  11  17  9  18 11 
Treated as outpatients            
Public  26 28 19 20 22 19 
Private  74 72 81 80 78 81 
Treated as inpatients            
Public  60 60 44 43 42 38 
Private  40 40 56 57 58 62 
Source: Indian National Sample Survey Organization (1992, 1998) as cited in Peters, Yazbeck and others, 
Better Health systems for India's Poor, 2002, Chapter 2, Table 2.4, p.48. 
 
 
The two panels of Figure 7, analyze the public/private roles from the expenditure 
perspective, comparing the South Asia region to sub-Saharan Africa. Panel a) of Figure 6 
shows that unlike total health expenditure, public health expenditure is distributed very 
differently in the two regions, with African governments being typically more generous than 
South Asian ones. While the median country in South Asia covers only about one fifth of 
health care costs out of public money (with India covering even less and Sri Lanka much 
more), the median country in Africa covers about half of health expenditure. 
Figure 7. South Asian countries offer less public financing and less insurance financing 
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Source: Author’s charts from World Bank, 2007. 
 
Whether low public funding makes health care accessible depends on how much of the 
balance must be covered by the patient out of pocket. Panel b of Figure 6 shows that there 
is generally a negative relationship between the share of total health expenditure covered 
by government and the share covered by patients out-of-pocket for both South Asian and 
Panel (b) Out-of-pocket expenditure share vs. 
public expenditure share 
Panel (a) Public share of health expenditures   13   
 
sub-Saharan countries.
7 This is not surprising, since the private individual’s percentage 
contribution plus the government’s percentage contribution cannot exceed 100. If the 
government and the private person’s out-of-pocket payments were the only contributors to 
financing health care, all of the countries in both regions would lie exactly on the straight 
line which is at a 45 degree angle from the two axes.
8 The reason that the country markers 
are not on the downward sloping diagonal is that some patients’ costs in every country are 
partly covered by a “third-party payer”. These “third-parties” might be public or private 
insurance schemes or employers. The farther a country marker is to the southwest of the 
downward sloping straight line, the larger the share that third-party payments assume of 
the total cost of medical care in that country. For example, the country that is farthest from 
the diagonal is South Africa, with Botswana, Zimbabwe and Uganda also having substantial 
coverage of private health expenditure from third party payers. In contrast, none of the 
South Asian countries benefits from more than 9 percent coverage of health care 
expenditure by third-party payers. Sri Lanka and Nepal have the most developed health 
insurance systems, covering about 8.7 percent of total expenditure. In India the coverage of 
third-party payers in 2004 was only 5.1 percent.
9 
Access to Private Health Care and the Risk of Poverty 
When a household has no access to subsidized public health care and no third-party 
coverage, it is completely exposed to the possibility of severe sickness episodes and the 
health care expenses that they entail. Traditional analyses of poverty use household 
expenditure to gauge the household’s well-being. But a household that has experienced life-
threatening illness will sell assets and borrow in order to finance higher-than-normal health 
care expenditure. Analysis of total household expenditure per capita makes it appear that 
such a household is doing very well, simply because they spends a lot. Only by netting out 
the health care expenditure can one approximate the household’s actual well-being. To the 
extent that South Asian AIDS patients are spending out-of-pocket for AIDS treatment, one 
can surmise that their household expenditure will be similarly inflated.  
In studies of a number of European and Asian countries, Adam Wagstaff, Edie Van 
Doorslaer and their coauthors have developed an interesting graphic technique for 
displaying the impact on poverty of sickness episodes and the consequent health care 
                                             
7 To a different degree in each country, the cost of both AIDS and non-AIDS care is currently 
underwritten by donors.  For example, according to India’s NACO, the Government of India covers 60 
percent of NACO’s budget out of either direct budget support or a credit from the World Bank.  The 
remaining 40 percent of NACO’s expenditures was funded by grants from DFID, the Global Fund on 
AIDS, TB & Malaria and USAID. (http://www.nacoonline.org/About_NACO/Funds_and_Expenditures/)  
8 A reviewer points out that the angle may appear different from 45 degrees if the printer chooses an 
aspect ratio other than one-to-one.   
9 A new initiative entitled the Indian National Health Insurance Program may dramatically increase 
insurance coverage in India (Range, 2008).     14   
 
expenditure in the absence of government subsidies or insurance coverage. Figure 8 is 
reproduced from their analysis of Bangladeshi household expenditure in 2000 where hardly 
any patients were paying for AIDS treatment. The upward sloping curve displays the 
cumulative distribution of household expenditure in Bangladesh. The vertical axis measures 
the household’s expenditure per member per day in multiples of the poverty line of US$1.08 
per day. A second horizontal line is constructed at another less-strict poverty line of US$2.15 
per day. The overall distribution shows that according to conventional measures, about 20% 
of the Bangladeshi population lived in households where daily consumption was less than 
US$1.08 per day and about 70% lived in households below US$2.15 per day.  
Figure 8. Impact of health expenditure on household net consumption patterns in Bangladesh 
 
Source: Van Doorslaer and others, 2006. Vertical lines represent reductions in 
household expenditure per capita caused by health spending: Lines that drop below 
the poverty line represent individuals pushed into poverty by health expenditure in 
2000.    15   
 
However, these conventional calculations omit consideration of health expenditure. The 
downward dropping “paint-drips” from the curved shape of the cumulative expenditure 
distribution show the effect of subtracting out-of-pocket health expenditure from total 
expenditure. The impact of this “correction” to the traditional measure of household well-
being is dramatic for some households, bringing their net consumption per household 
member below one of the poverty lines. Health expenditure large enough to reduce a family 
to penury can be fairly classified as “catastrophic”. Note that even households that would 
otherwise have been in the top decile of household expenditure were reduced to poverty by 
one of the two measures once health expenditure was netted out of their annual 
consumption.
 10 
Figure 8 dramatically depicts the problem of catastrophic health expenditure in 
Bangladesh, but unavoidably overstates the prevalence of the problem. For one of the 
vertical “paint-drips” to be visible to the reader, the line must have a certain width. Given 
the horizontal dimension of the printed page, even a small number of “paint-drips” will 
occlude the surface of the page, making it look as if virtually all households suffer 
substantial reductions in well-being from health expenditure. Consequently the only way to 
assess the prevalence of the problem of catastrophic out-of-pocket health expenditure is to 
consider a table that gives the percentage of individuals whose household expenditure net 
of health care costs is in fact below the poverty line. 
Table 3, which is excerpted from Van Doorslaer et al (2004), presents the impact on 
poverty in four South Asian countries of analyzing household expenditure per capita net of 
health expenditure rather than including it. In India, this re-definition of poverty would push 
an additional 20.6 million below the higher poverty line and 37.4 million people below the 
lower one, increasing the proportion of Indian’s suffering from the most extreme form of 
poverty by 12 percent. In Bangladesh, Nepal and Sri Lanka, health expenditure increases 
the number of those below the lower poverty line by 17, 6 and 8 percent respectively. 
Although these increases in measured poverty are smaller than might be inferred from 
Figure 8, they are nevertheless substantial.  
Many who have sought private sector treatment for AIDS are likely to have been pushed 
below the poverty line. Suppose that an individual spends approximately $365 a year out-of-
                                             
10 The situation is a bit more complex than presented in the text. Since people have insurance and 
precautionary saving, some of out-of-pocket payments are pre-financed and therefore should not be 
seen as immiserating. This pre-financed proportion of the OOP payments should instead be 
subtracted from both gross and net consumption. In Figure 8, this would have the effect of shifting 
an individual “paint-drip” to the left and also making it shorter. If the slope of the cumulative 
expenditure curve is sufficiently flat (i.e. less than 45 degrees) such a shift could move an individual 
who appears to be immiserated by health care expenditures to a position from which health 
expenditure no longer pushes him or her below the poverty line. See Van Doorslaer, Wagstaff and 
coauthors for in depth discussion (Van Doorslaer et al. 2007;Van Doorslaer, Wagstaff, and Rutten 
1993;Wagstaff 2002; Wagstaff, Van Doorslaer, and Paci 1989).    16   
 
pocket on AIDS treatment, which is enough to cover the full cost of first-line triple-drug 
therapy at generic prices plus doctor visits and some laboratory tests. In a four-person 
household, this would add $0.25 per member to daily health expenditure. From Figure 8 we 
can see that households at about the 40
th percentile of Bangladesh’s expenditure 
distribution, which had no other health expenditure, would be pushed down below the lower 
poverty line by a single AIDS patient, to be on a par with households at the 20
th percentile. 
Two AIDS patients in a household would severely impoverish a household which had 
previously been at the 45
th percentile of the expenditure distribution. 
Suppose that the distributions of overall expenditure and health expenditure for the 
poorest 40 percent of the Indian population are similar to those of the lowest 40 percent of 
the Bangladeshi population as depicted in Figure 8.  Further suppose that all of the 
estimated 500,000 to 1,600,000 people who are estimated to be living with AIDS in India 
are in households which would otherwise be above the $1.08 poverty line, but not above 
the 40
th percentile of the Indian income distribution.  Since there were between $300 and 
$500 million Indians living under the $1.08 poverty line in 2000, AIDS would increase the 
number of strictly poor by less than half of a percent.  In so doing it would increase the 
percentage of the population below the stricter poverty line by about 3 percent, from about 
35 percent to 38 percent.   
Table 3.  Poverty head counts: effect of accounting for out-of-pocket payments for health 
care, various years 
 
  Poverty line of $1·08 per day      Poverty line of $2·15 per day     
























Bangladesh  22·5% 26·3%  3·8%  4,940,585  16·8%  73·0% 76·5%  3·6%  4,653,875  4·9% 
India  31·1% 34·8%  3·7%  37,358,760  11·9%  80·3% 82·4%  2·1%  20,638,361  2·6% 
Nepal 39·3% 41·6%  2·2%  515,933  5·7%  80·4% 81·7%  1·3%  290,280  1·6% 
Sri Lanka  3·8%  4·1%  0·3%  60,116  8·3%  39·1%  40·8%  1·7%  325,783  4·3% 
Source: Van Doorslaer et al, Table 4 and the Equitap project working papers. 
 
This analysis does not take into account the fact that AIDS treatment must continue for 
the rest of the patient’s life. Most of the “paint-drips” in Figure 8 are probably associated 
with acute illness, not with chronic illness. A household might recover its economic status 
after a single catastrophic expenditure depresses their net expenditure for a single year. But 
that same household would need more robust coping strategies to deal with a stream of 
catastrophic expenditures over several years. To analyze chronic disease, one would need a 
graph like Figure 8 which would be constructed for wealth (or “permanent income”) instead 
of expenditure. 
In order to push this analysis further, it would be useful to have information on the 
distribution of South Asian HIV infections across the income or expenditure distributions 
depicted in graphs like Figure 8.  Reports of mostly poor people accessing government    17   
 
subsidized antiretroviral therapy in the last few years can be set against anecdotes and 
rumors about the spread of AIDS among the relatively wealthy in Bollywood. Unfortunately 
until recently there has been no population-based information available on the distribution 
of HIV infection by socioeconomic class, in India or indeed in almost any country in the 
world.
11 The fact that India’s recent reassessment of the extent of HIV infection was based 
on a household survey offers hope that India will be able to correlate HIV infection to 
socioeconomic status for the first time.  
Even without data on the socioeconomic distribution of HIV infection in South Asia, the 
absence of either a large public presence in health care delivery or significant health 
insurance coverage for nineteen out of twenty South Asian citizens renders the population 
unusually vulnerable to the financial risk of catastrophic health expenditures to treat AIDS. 
The efforts by governments in the region to assume public sector responsibility for rolling 
out AIDS treatment is a movement against the trend towards private sector dominance in 
the health care market. The next section presents projections of the accumulating number 
of patients needing treatment and poses the question of whether the government 
subsidized care can grow fast enough to meet all of that demand. 
Quality of Private vs. Public ART 
The consequences for the quality and availability of AIDS treatment of a major private 
sector role in AIDS health care delivery in poor countries are largely unknown. One view is 
that the newer formulations of antiretroviral drugs are so inexpensive, convenient and easy 
to understand that private sector care might be as high in quality as public sector care and 
might extend treatment access to many people who could not otherwise obtain it in the 
South Asian countries. An alternative view is that private providers have insufficient 
incentive to support patient adherence to the drug regimen, without which the treatment 
will fail, and the patient may transmit a resistant form of HIV and then die. The worst 
possibility is that private sector distribution would expand rapidly in the form of casual over-
the-counter sales of a heterogeneous and fluctuating mixture of full-strength, diluted and 
counterfeit antiretroviral medications, without any prescription or medical supervision.  This 
kind of private sector expansion is a recipe for exacerbating both the spread and the cost of 
the AIDS epidemic.  Within the complex private health care sectors in South Asian countries 
there are surely examples of both adherence maximizing and adherence minimizing private 
care. The heterogeneity of private care between these two extremes remains to be 
determined. Of course, similar questions can also be raised about the quality of public 
sector care. 
                                             
11 An early challenge to the assumption that HIV prevalence would be higher among the poor or 
uneducated is presented in Ainsworth & Over (1997).  The incorporation of blood tests into general 
purpose national surveys have shown that the highest HIV prevalence levels are often at mid or even 
at the highest levels of socioeconomic status in African countries (Montana, Neuman, Mishra and 
Macro International, 2007; Barnighausena, Hosegooda, Timaeus and Newella, 2007).     18   
 
To the extent that private care is less successful at supporting patient adherence to ART 
regimes than is the average public care facility, public financing of public sector ART 
delivery can be seen as crowding out some of the private sector care. If public sector care is 
less expensive to the patient than private care, and patients have at least a little knowledge 
of the relative merits of different service providers, the public sector care will be crowding 
out the worst of the private care, and thus preserving patient lives while stemming the 
development and spread of resistant strains of HIV.  
The possibility that publicly provided AIDS treatment might crowd out lower quality private 
care is an unusual and notable feature of public sector AIDS treatment in South Asia.
12 
Usually when public subsidy or subsidized provision of a good or service crowds out private 
provision, any redistributive benefits that accrue must be weighed against the consequent 
efficiency losses. In this case, assuming that the public sector succeeds more than the low-
quality private sector at facilitating patient adherence, the crowding out is preventing 
negative spillovers and is thus contributing to an improvement in efficiency. Given the right 
magnitudes for these various effects, crowding-out could provide a sufficient justification for 
public financing and provision even in the absence of the distributive arguments. 
Model delivery of ART includes the following essential components: (i) standardized, 
competency-based, training of physicians in ART management; (ii) prescription of a 
standard triple-drug regimen; (iii) support from a multidisciplinary team including a 
counselor and a nutritionist; (iv) regular clinical and laboratory-based monitoring of the 
patient’s treatment status; (v) counseling to prevent transmission; (vi) prophylaxis for 
opportunistic illnesses when indicates; and (vii) diagnosis and treatment of opportunistic 
illnesses (Over and others, 2006). Thus, the question of whether private sector delivery of 
ART would improve or worsen the quality of care in South Asia, depends on what proportion 
of the privately delivered ART meets these criteria.  
In previous work, this author and his co-authors have conjectured that the private 
sector care used by India’s poorest AIDS patients would be “unstructured” in the sense that 
it would not typically include these seven essential components and have modeled the 
impact of these assumptions on the future fiscal burden of AIDS treatment in that country 
                                             
12 Deolaliker and others (2008) argue that public spending on any type of health care can achieve 
equity goals by crowding out private out-of-pocket spending by the poor.  However, they also say 
that “[i]ncreasing public spending on health can be justified only if it yields health benefits” (ibid, p. 
980).  This would only be the case if public sector health spending improves health status enough to 
more than offset the reduction in health status due to the crowding out of private health spending.  
Whether publicly financed or provided health care is much more effective than privately financed or 
delivered care will depend a great deal on the context, but it might be especially true for services 
delivered to the poor and uneducated which generate negative spillovers when incompetently 
performed.  The efficiency argument for public intervention to assure the quality of health care 
delivery is thus particularly strong for diseases like AIDS, TB and malaria for which low quality 
treatment accelerates the development and spread of drug resistance.      19   
 
(Over and others, 2004). Since the publication of that book, only a single study has been 
published that addresses this conjecture. Sheikh and coauthors interviewed 215 providers in 
Pune, India and found that three-quarters of them had been consulted by HIV-infected 
clients. Of these, 14 percent had prescribed ART, “sometimes without adequate knowledge 
of the guidelines for their use” (Sheikh and others, 2005).  
On the other hand, it is not clear that public sector ART programs will necessarily be of 
higher quality. One study analyzed the treatment of 32 HIV/AIDS patients prior to 2004 at 
the B. P. Koirala Institute of Health Sciences, a major teaching hospital in eastern Nepal 
(Shrestha, Bhatta, and Bhatta, 2006). Thirteen of these were discharged with virtually no 
care. Among the rest, six of the seven OI prescriptions and all of the four ART prescriptions 
were incorrect. The authors concluded that “the care of HIV-infected patients even at a 
major tertiary care teaching hospital in Nepal [was] sub-optimal.” Since the Nepalese 
government has invested in the expansion of ART since 2003, a new study would hopefully 
reveal substantial improvement.  
In a study of the quality of the delivery of general outpatient medical services (where 
there was no HIV diagnosis), Das and Hammer found that quality was extremely variable in 
the public as well as the private programs (Das and Hammer 2004). But deviations from 
best practice care occurred in different directions and for different reasons in the two 
sectors. According to the authors, “[i]n the public sector providers are more likely to commit 
errors of omission - they are less likely to exert effort compared with their private 
counterparts. In the private sector, providers are prone to errors of commission - they are 
more likely to behave according to the patient's expectations, resulting in the inappropriate 
use of medications, the overuse of antibiotics, and increased expenditures”. 
Both types of errors, of omission or commission, threaten the quality and therefore the 
success of AIDS treatment in India. Either can lead to early treatment failure for the patient 
and transmission by the patient of a drug resistant strain of HIV to someone who 
consequently requires much more expensive second-line or salvage drug therapy. Thus, a 
government that is committed to providing subsidized AIDS treatment to all has an 
important role to play in assuring minimum quality standards for AIDS care in the private as 
well as the public sector.
13  
Conclusions 
To the extent that patients seek out and obtain good quality AIDS treatment from the 
private sector, South Asian governments can achieve the benefits of rapid scale up without 
directly bearing the costs. However, it is difficult to project what the share of private 
treatment is now or will be in the future. If HIV infections are evenly distributed across the 
                                             
13 High quality AIDS treatment will not only maximize adherence, and thus patient survival, but will 
also minimize transmission in the community through outreach programs. Potential mechanisms to 
achieve this goal are discussed in Over and others (2006) and Over and others (2007).    20   
 
range of South Asian living standards, then only 30 percent of the cases would be above the 
more generous poverty line of US$2.15. And the poorest 10 percent of these (the third 
decile of the expenditure distribution) would be pushed down into poverty by AIDS 
treatment expenditures. Under these assumptions, only 20 percent of AIDS patients could 
afford to pay for treatment without becoming impoverished.  Without government subsidy, 
AIDS treatment would be beyond the reach of 80 percent of patients.   
Against this background, the South Asian governments have three choices. They can 
strive to meet the goal of universal access as best they can with public delivery of ART. This 
policy will lead to the greatest expansion in costs and incidentally will swim against the 
current of the increasing privatization of South Asian health services.
14 They can allow the 
expansion of private AIDS care for those who can afford it, while trying to reduce its cost 
and assure its quality.  Or they can use the AIDS epidemic as one more incentive to push 
for greater health insurance and other third-party payment of health care costs. The latter 
policy would be difficult to follow in a population with extremely high prevalence rates, 
because AIDS treatment is an expensive risk and would raise issues of adverse selection.  
But a policy to expand health insurance which includes coverage of AIDS treatment may 
succeed in India and other South Asian countries where a diagnosis of HIV positive is still 
relatively rare.  For example, India could experiment with adding AIDS treatment to its 
recently launched National Health Insurance Program, provided that the government 
authorizes the reimbursement of antiretroviral medication when delivered by providers who 
have received accredited training in that specialization and submit to rigorous periodic 
supervision (Range, 2008).
15 
Whether or not the South Asian governments decide to explicitly encourage private 
sector delivery of AIDS care, they have a fundamental responsibility to collect data on the 
quality of both public and private AIDS care. Only through data collection on both types of 
AIDS care will it be possible to gauge the quality difference between the local public and 
private delivery systems. Since private providers may have little incentive to retain clients 
over the many months and then years required for treating this chronic illness, regulation of 
the private AIDS treatment sector is recommended. Depending on the findings of such a 
data collection and monitoring project the government could decide to accelerate public 
                                             
14 A reviewer points out that the government of India has recently committed to increasing health 
expenditure from its present 1 percent of GDP to 2 – 3 percent of GDP by 2012.  This paper shows 
that expansion of AIDS treatment could potentially absorb all of such an increase.   
15 Provided that HIV infection remains rare, enrollees are risk adverse and enrollment procedures in 
the new National Health Insurance Program effectively minimize adverse selection into the program 
of those who are more likely to be HIV infected, inclusion of ART could enhance the consumer 
surplus provided by the program’s benefit package by more than it increases its costs.  Thus it would 
be efficient as well as equitable to cover ART with insurance.  In contrast, an analysis along cost-
effectivness lines such as that in Deolaliker and others (2008) would exclude ART as less cost-
effective than other interventions.    21   
 
provision (in order to crowd out the lowest end of the AIDS care spectrum) or to develop 
explicit strategies for delegating a part of the care burden to the private sector. It might be 
necessary to do both, each with a different segment of the private market.    22   
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ANNEX 1. PROJECTED FISCAL BURDEN OF AIDS TREATMENT IN FOUR SOUTH ASIAN COUNTRIES
16 

























Total number on ART Number on 2nd Line































2005 2010 2015 2020



















2005 2010 2015 2020


















2005 2010 2015 2020
ART % Pub HE ART % Total HE
ART % Cntrl Gov Exp
Adjusting at 95.0 % of unmet need each year
adrate1 = .13, adrate2 = .04, bdrate = .01, Erate = .11, ndrate = .3, incdwn = .95
Total for country BGD
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16 In the southwest panel of each figure the term “entitlement” refers to that portion of total 
expenditures in any given year that sustains patients who have survived on treatment from a 
previous year, while the term discretionary refers to expenditures on patients newly recruited to 
treatment in the current year.  See Over (2008) for a discussion of this terminology as applied to the 
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ANNEX 3. A MODEL FOR PROJECTING FUTURE AIDS TREATMENT COSTS
17  
Projections of future treatment costs were made using a simple difference equation model based 
on those used in previous modeling studies of AIDS treatment in India (Over et al. 2004) and 
Thailand (Over et al. 2006).  The prototype model was developed using Modelmaker from 
ModelKinetix (http://www.modelkinetix.com/) and then ported to STATA.  The STATA code is 
available from the author on request. 
  The following figure provides a flow diagram of the model’s difference equations as 
implemented by the STATA program aidsproj.ado .  The dark lines with arrow heads indicate flows 
from a source to a sink.  Parameter names close to those arrow heads are defined below the figure.  
Most of them are annual rates of flow expressed as proportions of the source population that move 
towards the sink in a single year.  However, the parameter “Cvrg2” represents the proportion of 
patients needing second line therapy who gain access to it in a given year.  The runs of the model 
reported here assume that coverage with second-line therapy starts at 5 percent of those needing it 
in 2006 and levels off at 95 percent of those needing it in 2016. 
Flow diagram for aidsproj model predicting the future growth of AIDS treatment costs 
 
                                             
17 See the Spectrum projection model for an alternative approach: http://www.futuresinstitute.org/.    29   
 
 
Parameters of the aidsproj projection model 
 
 Proportion of HIV+ newly eligible for ART            erate       .11 
 ART Death Rate during first year on 1st line           adrate1    .13 
 ART Failure Rate during subsequent years on 1st line     adrate2    .04 
 ART Death Rate of AIDS patients on 2nd line           bdrate    .01 
 Non-ART Death Rate of AIDS patients               ndrate    .3 
 Starting coverage rate for 2nd line ART
18             strtcov2   .05 
 Target coverage rate for 2nd line ART              trgtcov2   .95 
 2nd line ART to reach target in year               trgtyr       2016 
Scale-up of 1st line modeled as constant proportion (1 - lambda) of unmet need, where 
lambda is constant across all countries and equal to: 
    Historical scale up           lambda =       .82 
    Rapid scale up             lambda =       .05 
Annual cost per patient of first-line drugs
19      $227 
Annual cost per patient of second-line drugs         $2,681 
Annual cost per patient of clinic time           $278 
                                             
18 The model embodies the assumption that, for those people who fail first-line ART, access to 
second-line ART expands along a logistic curve from about 5 percent of all patients needing it now to 
95% of all patients needing it in 2016.  
19 Drug costs are assumed to vary across countries with the 2006 GDP per capita of the country 
according to the patterns observed by WHO in that year and then to remain constant (in constant 
dollars) in any given country over time. While the costs of drugs may be reduced as markets for 
antiretroviral drugs become more contestable, the unit costs of achieving high ART uptake and strong 
adherence may increase at the same rate, leaving average costs per patient unchanged.     30   
 
ANNEX 4. PROJECTED ANNUAL COST OF TREATING AIDS PATIENTS IN 6 SOUTH ASIAN COUNTRIES BY 
UPTAKE AND PREVENTION SCENARIOS (2006 US DOLLARS) 
 
Costs of AIDS treatment at historical 
uptake with effective prevention 
(90% reduction in incidence each year)     
Costs of AIDS treatment at historical 
uptake with moderate prevention 
(5% reduction in incidence each year) 
  1st line  2nd line  Total cost      1st line  2nd line  Total cost 
2006 26,991 7,673  34,664    2006  26,991 7,673  34,664 
2007 40,188 8,071  48,259    2007  40,188 8,071  48,259 
2008 52,467 9,102  61,569    2008  52,467 9,102  61,569 
2009 64,405  11,313  75,718    2009  64,405  11,313  75,718 
2010 75,425  15,087  90,512    2010  76,001  15,087  91,088 
2011 85,236  20,780  106,016    2011  87,218  20,780  107,998 
2012 93,718  28,679  122,397    2012  98,019  28,734  126,753 
2013 100,865 38,979  139,844    2013  108,363 39,270  147,633 
2014 106,732 51,806  158,538    2014  118,206 52,677  170,883 
2015 111,410 67,205  178,615    2015  127,511 69,213  196,724 
2016 115,008 85,176  200,184    2016  136,255 89,109  225,364 
2017 117,630  103,798  221,428    2017  144,420  110,451  254,871 
2018 119,396  122,889  242,285    2018  151,987  133,122  285,109 
2019 120,401  142,267  262,668    2019  158,953  157,014  315,967 
2020 120,747  161,774  282,521    2020  165,319  182,005  347,324 
Total 1,350,619  874,599 
Least costly 
2,225,218    Total 1,556,303  933,621  2,489,924 
                
 
Costs of AIDS treatment at rapid uptake 
with effective prevention 
(90% reduction in incidence each year)    
Costs of AIDS treatment at rapid uptake 
with moderate prevention 
(5% reduction in incidence each year) 
  1st line  2nd line  Total cost      1st line  2nd line  Total cost 
2006 26,991 7,673  34,664    2006  26,991 7,673  34,664 
2007 258,193  8,071  266,264    2007  258,193  8,071  266,264 
2008 319,797  9,102  328,899    2008  319,797  9,102  328,899 
2009 388,257 23,025  411,282    2009  388,257 23,025  411,282 
2010 445,754 46,425  492,179    2010  455,046 46,425  501,471 
2011 492,955 81,134  574,089    2011  519,393 81,134  600,527 
2012 531,116  128,198  659,314    2012  580,896  129,118  710,014 
2013 561,384  188,133  749,517    2013  639,259  192,155  831,414 
2014 584,774  261,115  845,889    2014  694,262  271,843  966,105 
2015 602,187  347,036  949,223    2015  745,756  369,568 1,115,324 
2016 614,414  445,581  1,059,995    2016  793,646  486,518 1,280,164 
2017 622,159  546,294  1,168,453    2017  837,891  611,374 1,449,265 
2018 626,036  648,227  1,274,263    2018  878,483  743,426 1,621,909 
2019 626,595  750,576  1,377,171    2019  915,451  881,967 1,797,418 
2020 624,316  852,648  1,476,964    2020  948,854  1,026,292 1,975,146 
Total 7,324,928  4,343,238  11,668,166    Total 9,002,175 4,887,691 
Most costly 
13,889,866 
Source: Author’s calculations based on assumptions in Annex 3. 
 
 